However, we found that high levels of BGN predict poor prognosis in GC patient diagnosed with advanced stages of the disease (stage III: HR=1.98, 95% CI = 1.37–2.88, p value < 0.001; stage IV: HR = 1.87, 95% CI = 1.17–2.98, p value = 0.008) (Figure 1I), also being associated with tumor recurrence (HR = 1.52, 95% CI = 1.19–1.95, p value < 0.001) (Figure 1J) and post-progression survival (HR = 2.16, 95% CI = 1.66–2.81, p value < 0.001) (Figure S2L). This evidence concerns the gene BGN and neoplasm.